APEA Pharmacology Final Exam 2 –
2026 Edition With Questions And
Answers With Rationales/Graded
A+/2026 Update/100% Correct
Section 1: Cardiovascular Pharmacology (Questions 1-15)
1. A 68-year-old with HFrEF (EF 30%) on optimal GDMT presents with
worsening dyspnea. Which agent has shown the most significant mortality
benefit when added to sacubitril/valsartan in 2026 guidelines?
A) Digoxin
B) Ivabradine
C) SGLT2 inhibitor (dapagliflozin)
D) Hydralazine
Rationale: 2026 HF guidelines recommend SGLT2 inhibitors
(dapagliflozin/empagliflozin) as first-line adjunct to ARNI for HFrEF regardless of
diabetes status, reducing CV death/HHF by 26%.
2. Which anticoagulant requires dose adjustment for CYP3A4 and P-gp
interactions and has a specific reversal agent (andexanet alfa)?
A) Warfarin
B) Dabigatran
C) Rivaroxaban
D) Edoxaban
Rationale: Rivaroxaban (factor Xa inhibitor) is metabolized by CYP3A4;
andexanet alfa reverses rivaroxaban/apixaban. Dabigatran reversed by
idarucizumab.
3. A patient on amiodarone develops pulmonary fibrosis. What is the most
critical next step?
A) Add prednisone
B) Discontinue amiodarone immediately
C) Switch to dronedarone
D) Obtain bronchoalveolar lavage
, Rationale: Amiodarone-induced pulmonary toxicity requires drug cessation;
continued use can be fatal. Corticosteroids may be adjunctive but not primary.
4. Which statin has the highest risk of drug-induced myopathy when
combined with gemfibrozil?
A) Atorvastatin
B) Pravastatin
C) Rosuvastatin
D) Pitavastatin
Rationale: Gemfibrozil inhibits OATP1B1 and glucuronidation, raising
rosuvastatin levels >2-fold. Fenofibrate is safer with statins.
5. A 55-year-old with paroxysmal AF and CrCl 25 mL/min needs stroke
prevention. Which DOAC is preferred?
A) Rivaroxaban 20 mg daily
B) Dabigatran 150 mg BID
C) Apixaban 5 mg BID
D) Edoxaban 60 mg daily
Rationale: Apixaban has only 25% renal excretion; approved in CrCl ≥15
mL/min. Rivaroxaban and edoxaban require CrCl >30 mL/min.
6-15. (Additional CV questions on antiplatelet therapy, beta-blocker titration,
amlodipine edema management, etc.)
... (Shortened for space; full exam continues similarly)
Section 2: Diabetes & Metabolic Agents (Questions 16-25)
16. According to 2026 ADA standards, which agent is recommended as first-
line therapy for T2DM with established CKD (eGFR 25-45) and albuminuria?
A) Metformin
B) SGLT2 inhibitor (empagliflozin)
C) GLP-1 agonist (semaglutide)
D) DPP-4 inhibitor
Rationale: SGLT2 inhibitors reduce CKD progression and CV death regardless of
glycemic control; metformin is safe but not renoprotective alone.
17. Which GLP-1 receptor agonist has the strongest evidence for reducing
major adverse cardiovascular events (MACE)?
A) Exenatide
2026 Edition With Questions And
Answers With Rationales/Graded
A+/2026 Update/100% Correct
Section 1: Cardiovascular Pharmacology (Questions 1-15)
1. A 68-year-old with HFrEF (EF 30%) on optimal GDMT presents with
worsening dyspnea. Which agent has shown the most significant mortality
benefit when added to sacubitril/valsartan in 2026 guidelines?
A) Digoxin
B) Ivabradine
C) SGLT2 inhibitor (dapagliflozin)
D) Hydralazine
Rationale: 2026 HF guidelines recommend SGLT2 inhibitors
(dapagliflozin/empagliflozin) as first-line adjunct to ARNI for HFrEF regardless of
diabetes status, reducing CV death/HHF by 26%.
2. Which anticoagulant requires dose adjustment for CYP3A4 and P-gp
interactions and has a specific reversal agent (andexanet alfa)?
A) Warfarin
B) Dabigatran
C) Rivaroxaban
D) Edoxaban
Rationale: Rivaroxaban (factor Xa inhibitor) is metabolized by CYP3A4;
andexanet alfa reverses rivaroxaban/apixaban. Dabigatran reversed by
idarucizumab.
3. A patient on amiodarone develops pulmonary fibrosis. What is the most
critical next step?
A) Add prednisone
B) Discontinue amiodarone immediately
C) Switch to dronedarone
D) Obtain bronchoalveolar lavage
, Rationale: Amiodarone-induced pulmonary toxicity requires drug cessation;
continued use can be fatal. Corticosteroids may be adjunctive but not primary.
4. Which statin has the highest risk of drug-induced myopathy when
combined with gemfibrozil?
A) Atorvastatin
B) Pravastatin
C) Rosuvastatin
D) Pitavastatin
Rationale: Gemfibrozil inhibits OATP1B1 and glucuronidation, raising
rosuvastatin levels >2-fold. Fenofibrate is safer with statins.
5. A 55-year-old with paroxysmal AF and CrCl 25 mL/min needs stroke
prevention. Which DOAC is preferred?
A) Rivaroxaban 20 mg daily
B) Dabigatran 150 mg BID
C) Apixaban 5 mg BID
D) Edoxaban 60 mg daily
Rationale: Apixaban has only 25% renal excretion; approved in CrCl ≥15
mL/min. Rivaroxaban and edoxaban require CrCl >30 mL/min.
6-15. (Additional CV questions on antiplatelet therapy, beta-blocker titration,
amlodipine edema management, etc.)
... (Shortened for space; full exam continues similarly)
Section 2: Diabetes & Metabolic Agents (Questions 16-25)
16. According to 2026 ADA standards, which agent is recommended as first-
line therapy for T2DM with established CKD (eGFR 25-45) and albuminuria?
A) Metformin
B) SGLT2 inhibitor (empagliflozin)
C) GLP-1 agonist (semaglutide)
D) DPP-4 inhibitor
Rationale: SGLT2 inhibitors reduce CKD progression and CV death regardless of
glycemic control; metformin is safe but not renoprotective alone.
17. Which GLP-1 receptor agonist has the strongest evidence for reducing
major adverse cardiovascular events (MACE)?
A) Exenatide
